$LGI

Lazard Global Total Return & Inc Fd Inc's Dividend Analysis

Lazard Global Total Return & Income Fund (NYSE:LGI) announced a total dividend of $0.15 per share, with an ex-dividend date of 2026-08-10 and a payable date of 2026-08-21. The article cites GuruFocus data, noting LGI’s monthly dividends since 2004 and a 12-month trailing dividend yield of 9.80% and forward yield of 9.83%.

Original reporting
Published Aug 10, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Lazard Global Total Return & Inc Fd Inc's Dividend Analysis — source image
Decision brief

The 30-second read

$LGINeutralLow
01

Why it matters

The only actionable new item is the declared dividend amount and the ex-dividend and payable dates; the rest is general dividend-sustainability commentary using yield figures.

02

Market read

Traders may adjust short-term positioning around the ex-dividend date, but there is no new fundamental catalyst beyond the payout announcement.

03

What to watch

The article does not include coverage metrics, UNII, NAV trend, or leverage/cost changes, which are key to assessing whether the dividend is sustainable beyond the next payment.

Relevance 4/10Novelty 4/10Timing: ex-dividend date is 2026-08-10, payment scheduled for 2026-08-21

Background

The piece frames LGI as a diversified closed-end management investment company with monthly dividends and discusses yield and dividend history.

Company-level read

Ticker impact

$LGINeutralMedium confidence
Context

LGI announced a $0.15 per share cash dividend with an ex-dividend date of 2026-08-10 and payment on 2026-08-21.

Expected impact

Likely limited, mostly mechanical impact around the ex-dividend date; any move should fade after the payout window.

Evidence & confidence

For closed-end funds, dividend declarations can affect short-term demand from yield buyers, but the article does not provide new fundamentals beyond the declared payout and yield metrics.

Market effects

Minimal sector read-through; this is fund-specific dividend timing and yield discussion rather than a broader CEF policy shift.

None indicated beyond US-listed closed-end fund income flows.

None indicated.

Counterpoint

A high stated yield can reflect market concerns about distribution sustainability, so the declared monthly payout may not reduce downside risk if underlying earnings or NAV pressure persists.

Key entities

  • Lazard Global Total Return & Inc Fd Inc

    Subject of the article, with a declared $0.15/share monthly cash dividend and specified ex-dividend and payment dates.

Related articles

$ALOYMed

Why Trump Can't Afford to Lose The Rare Earth Race

REalloys (NASDAQ: ALOY) has assembled a rare earth manufacturing process from feedstock to magnet production, aiming to reduce reliance on China. The company secured raw materials, built a metallization platform, and partnered for magnet manufacturing. It raised $100M to finance its operations, targeting commercial production by early 2027 to meet Pentagon demand for non-Chinese rare earth magnets.

$NBISHigh

Nebius borrows $3.5 billion as investors question neocloud debt

Nebius Group N.V. (NBIS) secured a $3.5 billion loan from Citigroup, maturing in 364 days. The company's revenue chief noted rising AI computing prices and distinguished Nebius from CoreWeave Inc. (CRWV) regarding debt levels. The loan, priced at Term SOFR plus 2.75-3.5%, will fund data centers and GPUs, adding to existing convertible bonds. Nebius also began publishing live spot prices for GPU capacity, aiming to optimize long-term financing costs.

$ZLABHighAI 9/10

Zai Lab Limited Prices $250M PIPE at $22.04 Per ADS

Zai Lab Limited announced a private placement of 11.34 million American Depositary Shares (ADSs) at $22.04 each, raising $250 million. The deal is expected to close by October 27, 2026, subject to conditions. The funds will support the development of an oncology asset.